Display options
Cite
Choi JS, Yoon D, Koo JS, et al. Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers. Oncotarget. 2017;8(38):63405-63416doi: 10.18632/oncotarget.18822.
Choi, J. S., Yoon, D., Koo, J. S., Kim, S., Park, V. Y., Kim, E. K., Kim, S., & Kim, M. J. (2017). Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers. Oncotarget, 8(38), 63405-63416. https://doi.org/10.18632/oncotarget.18822
Choi, Ji Soo, et al. "Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers." Oncotarget vol. 8,38 (2017): 63405-63416. doi: https://doi.org/10.18632/oncotarget.18822
Choi JS, Yoon D, Koo JS, Kim S, Park VY, Kim EK, Kim S, Kim MJ. Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers. Oncotarget. 2017 Jun 28;8(38):63405-63416. doi: 10.18632/oncotarget.18822. eCollection 2017 Sep 08. PMID: 28969000; PMCID: PMC5609932.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 Jun 28;8(38):63405-63416. doi: 10.18632/oncotarget.18822. eCollection 2017 Sep 08.

Magnetic resonance metabolic profiling of estrogen receptor-positive breast cancer: correlation with currently used molecular markers.

Oncotarget

Ji Soo Choi, Dahye Yoon, Ja Seung Koo, Siwon Kim, Vivian Youngjean Park, Eun-Kyung Kim, Suhkmann Kim, Min Jung Kim

Affiliations

  1. Department of Radiology, Breast Cancer Center, Samsung Medical Center, Seoul, Korea.
  2. Department of Chemistry, Center for Proteome Biophysics and Chemistry Institute for Functional Materials, Pusan National University, Busan, Korea.
  3. Department of Pathology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
  4. Department of Forensic Chemistry, National Forensic Service Busan Institute, Yangsan-si, Korea.
  5. Department of Radiology, Research Institute of Radiological Science, Yonsei University College of Medicine, Seoul, Korea.

PMID: 28969000 PMCID: PMC5609932 DOI: 10.18632/oncotarget.18822

Abstract

Estrogen receptor (ER)-positive breast cancers overall have a good prognosis, however, some patients suffer relapses and do not respond to endocrine therapy. The purpose of this study was to determine whether there are any correlations between high-resolution magic angle spinning (HR-MAS) magnetic resonance spectroscopy (MRS) metabolic profiles of core needle biopsy (CNB) specimens and the molecular markers currently used in patients with ER-positive breast cancers. The metabolic profiling of CNB samples from 62 ER-positive cancers was performed by HR-MAS MRS. Metabolic profiles were compared according to human epidermal growth factor receptor 2 (HER2) and Ki-67 status, and luminal type, using the Mann-Whitney test. Multivariate analysis was performed with orthogonal projections to latent structure-discriminant analysis (OPLS-DA). In univariate analysis, the HER2-positive group was shown to have higher levels of glycine and glutamate, compared to the HER2-negative group (

Keywords: ER-positive; HR-MAS MRS (high-resolution magic angle spinning magnetic resonance spectroscopy); biomarker; breast cancer; luminal

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no competing interests.

References

  1. NMR Biomed. 2012 Nov;25(11):1271-9 - PubMed
  2. J Natl Compr Canc Netw. 2016 May;14 (5 Suppl):641-4 - PubMed
  3. Obes Rev. 2004 Aug;5(3):153-65 - PubMed
  4. Nat Med. 2002 Dec;8(12):1439-44 - PubMed
  5. Lancet. 2002 Jun 22;359(9324):2131-9 - PubMed
  6. NMR Biomed. 2010 May;23(4):424-31 - PubMed
  7. J Clin Oncol. 2009 Mar 10;27(8):1160-7 - PubMed
  8. Plant Mol Biol. 2002 Jan;48(1-2):155-71 - PubMed
  9. Breast Cancer Res. 2010;12(5):R76 - PubMed
  10. Cancer Res. 2007 Dec 1;67(23):11284-90 - PubMed
  11. J Clin Oncol. 2007 Jan 1;25(1):118-45 - PubMed
  12. PLoS One. 2013 Dec 19;8(12):e83866 - PubMed
  13. BMC Genomics. 2006 Apr 27;7:96 - PubMed
  14. Breast Cancer Res Treat. 2013 Jun;139(2):371-9 - PubMed
  15. Br J Cancer. 2007 May 21;96(10):1504-13 - PubMed
  16. NMR Biomed. 2012 Feb;25(2):369-78 - PubMed
  17. J Clin Oncol. 2007 Dec 20;25(36):5815-24 - PubMed
  18. Cancer Genomics Proteomics. 2014 Nov-Dec;11(6):279-94 - PubMed
  19. Breast Cancer Res. 2008;10(4):R65 - PubMed
  20. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  21. Ann Oncol. 2011 Aug;22(8):1736-47 - PubMed
  22. Trends Biochem Sci. 2010 Aug;35(8):427-33 - PubMed
  23. Int J Biochem Cell Biol. 2011 Jul;43(7):1010-20 - PubMed
  24. J Proteome Res. 2010 Feb 5;9(2):972-9 - PubMed
  25. Curr Pharmacogenomics Person Med. 2009 Dec 1;7(4):263-274 - PubMed
  26. Breast Cancer Res Treat. 2011 Feb;125(3):687-96 - PubMed
  27. FEBS J. 2012 Aug;279(15):2610-23 - PubMed
  28. J Hepatol. 2010 Feb;52(2):228-33 - PubMed
  29. Medicine (Baltimore). 2016 Apr;95(15):e3398 - PubMed
  30. Med Clin (Barc). 1991 Oct 26;97(14):542-51 - PubMed
  31. AJR Am J Roentgenol. 2012 May;198(5):W488-97 - PubMed
  32. NMR Biomed. 1992 Jul-Aug;5(4):179-84 - PubMed
  33. Expert Rev Mol Diagn. 2006 Nov;6(6):821-9 - PubMed
  34. NMR Biomed. 2002 Aug;15(5):327-37 - PubMed
  35. PLoS One. 2015 Mar 09;10(3):e0119473 - PubMed
  36. PLoS One. 2012;7(12):e51712 - PubMed
  37. Metabolism. 2013 Jul;62(7):961-9 - PubMed
  38. Metabolomics. 2005 Mar;1(1):3-9 - PubMed
  39. Cancer Causes Control. 2014 Feb;25(2):143-9 - PubMed
  40. Genome Med. 2012 Apr 30;4(4):37 - PubMed
  41. Am J Clin Pathol. 2008 Feb;129(2):263-73 - PubMed
  42. NMR Biomed. 2010 Jul;23(6):633-42 - PubMed
  43. J Clin Oncol. 2007 May 20;25(15):2127-32 - PubMed
  44. Radiol Clin North Am. 2007 Sep;45(5):881-94, vii - PubMed
  45. J Natl Cancer Inst. 2009 May 20;101(10):736-50 - PubMed
  46. Nat Genet. 2013 Dec;45(12):1446-51 - PubMed
  47. Mol Oncol. 2010 Jun;4(3):192-208 - PubMed
  48. Pflugers Arch. 2000 Jan;439(3):271-7 - PubMed
  49. BMC Cancer. 2010 Nov 16;10:628 - PubMed
  50. Clin Chem. 2013 Jan;59(1):138-46 - PubMed
  51. Lancet. 2005 May 14-20;365(9472):1687-717 - PubMed
  52. Clin Cancer Res. 2008 Aug 15;14(16):5158-65 - PubMed
  53. Ultrasonography. 2016 Oct;35(4):281-8 - PubMed
  54. PLoS One. 2011;6(10):e25563 - PubMed
  55. N Engl J Med. 2003 Nov 6;349(19):1793-802 - PubMed
  56. BMC Cancer. 2014 Dec 12;14:941 - PubMed
  57. PLoS One. 2016 Jul 26;11(7):e0159949 - PubMed
  58. Adv Anat Pathol. 2012 Jan;19(1):39-53 - PubMed
  59. Clin Cancer Res. 2014 Jul 15;20(14):3870-83 - PubMed
  60. J Clin Oncol. 2010 Jun 1;28(16):2784-95 - PubMed
  61. Br J Cancer. 2014 Jan 21;110(2):330-40 - PubMed

Publication Types